Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$19.32 ▲ +0.03
(+0.16%)
MKT CAP: $3.09B • VOL: 1.45M
52W L $14 52W H $27
DNLI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $330.5M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$555.3M | -$487.3M | -$196.7M |
| Operating Margin % | — | — | -59.5% |
| Net Income (GAAP) | -$512.5M | -$422.8M | -$145.2M |
| EBITDA (Normalized) | -$547.7M | -$474.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$412.6M | -$347.7M | -$358.0M |
| Capital Expenditures (CapEx) | $9.5M | $15.9M | — |
| Free Cash Flow (FCF) | -$422.1M | -$363.6M | -$358.0M |
| FCF Margin % | — | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -36.5% | — |
| Cash & Short-Term Equivalents | $205.3M | $175.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.01B | $1.23B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DNLI.